Aurinia Pharmaceuticals
AUPH
200 hedge funds and large institutions have $525M invested in Aurinia Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 64 increasing their positions, 50 reducing their positions, and 19 closing their positions.
100% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 19
28% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 50
22% more capital invested
Capital invested by funds: $429M → $525M (+$96.5M)
9% more funds holding
Funds holding: 183 → 200 (+17)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.09% less ownership
Funds ownership: 40.95% → 40.86% (-0.09%)
21% less call options, than puts
Call options by funds: $13.3M | Put options by funds: $16.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.79M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$8.78M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.93M |
| 4 |
Lazard Asset Management
New York
|
+$3.76M |
| 5 |
JP Morgan Chase
New York
|
+$3.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$14.7M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$8.65M |
| 3 |
Goldman Sachs
New York
|
-$5.35M |
| 4 |
SG Americas Securities
New York
|
-$3.96M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.09M |
AUPH Hedge Fund Activity: Q4 2024 in Review
200 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2024, worth a combined $525M — up 22% from $429M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AUPH positions and 19 closed out — a net gain of 19 holders — while 64 added to existing stakes and 50 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $9.79M. The largest seller was Armistice Capital, cutting an estimated $14.7M.
- 200 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2024, up from 183 in Q3 2024.
- Funds reported $525M of Aurinia Pharmaceuticals stock for Q4 2024, up 22% quarter-over-quarter.
- 38 funds opened new Aurinia Pharmaceuticals positions in Q4 2024 and 19 closed out, a net change of +19 holders.
- The largest Aurinia Pharmaceuticals buyer in Q4 2024 was Tang Capital Management, an estimated $9.79M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2024 was Armistice Capital, an estimated $14.7M sold.
Based on aggregated 13F filings for Q4 2024.